Esperion revenue surges 144% in Q4 on major milestone and expansion
Compartilhar
Esperion Therapeutics (NASDAQ:ESPR), the pharmaceutical company focused on lipid-management therapies, reported total revenue of $168.4 million for the fourth quarter, representing a 144% increase over the same period last year.
